–
68/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →Longevity · Senolytic
FOXO4-DRI
Released: Last reviewed:
FOXO4-DRI is a synthetic peptide designed to selectively induce apoptosis in senescent cells, a foundational mechanism of biological aging. Heavily studied in mouse models of aging.
FOXO4-DRI at a glance
FOXO4-DRI is a synthetic peptide designed to selectively induce apoptosis in senescent cells, a foundational mechanism of biological aging. Heavily studied in mouse models of aging. Mechanism: Senolytic peptide. Typical route: Intraperitoneal (animal); SC (human protocols). FDA status: Not FDA-approved. Available through research-chemical suppliers; clinical-grade compounded versions are uncommon. Human safety and efficacy data are essentially nonexistent.
Drug classSenolytic peptide
Half-lifeShort (hours)
RouteIntraperitoneal (animal); SC (human protocols)
Animal dosing5 mg/kg, intermittent
FDA statusNot approved
Available throughResearch suppliers
Mechanism of action
FOXO4-DRI disrupts the interaction between FOXO4 and p53 in senescent cells, releasing p53 to trigger apoptosis selectively in cells that have entered senescence. Healthy cells are spared. The result is a 'senolytic' clearance of accumulated senescent cells.
Dosing reference
Animal-protocol dosing: 5 mg/kg intraperitoneal, three doses over five days, repeated every several weeks. Human dosing is not standardized; clinical-trial data is absent.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
Not FDA-approved. Available through research-chemical suppliers; clinical-grade compounded versions are uncommon. Human safety and efficacy data are essentially nonexistent.
U.S. telehealth providers that work with FOXO4-DRI
–
88/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →–
80/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →–
85/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →Related longevity peptides
Frequently asked questions about FOXO4-DRI
Does FOXO4-DRI work in humans?
Human clinical-trial data is essentially absent. Mouse-model results are striking (reduced frailty, restored kidney and coat function) but cross-species extrapolation in senolytics has historically been imperfect.
Is FOXO4-DRI safe?
Long-term safety in humans is unknown. Senolytic mechanisms can theoretically have off-target effects on stem cells. We do not recommend self-experimentation outside of monitored clinical trials.
References
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16. PMID: 28340339
- Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cells. EBioMedicine. 2021;73:103646. PMID: 34749304
Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.